EMMA Vienna 2017 | Early identification of myeloma to prevent disease progression
Irene Ghobrial
• 27 Jan 2017
Irene Ghobrial, MD, of the Dana-Farber Cancer Institute, Boston, MA talks about the exciting new developments in myeloma research, which will allow doctors to define specific patients who will progress to myeloma, and potentially treat them early. She explains that over the recent years, there have been various successful clinical trials, where patients have been able to be treated early, and that more clinical trials are currently underway. Stopping myeloma before it progresses, could potentially cure thousands of people.
Recorded at the 2017 European Multiple Myeloma Academy (EMMA) in Vienna, Austria.
This program was sponsored by Celgene through an unrestricted educational grant to Video Journal of Hematological Oncology.
